Introduction {#sec1-1}
============

Cerebello-pontine angle (CPA) surgeries tend to carry the surgeon\'s knife uncomfortably close to the brainstem, putting various cranial nerves at risk for damage. Cranial nerve monitoring usually employed to circumvent such an adverse event, requires changes in anesthetic management by exclusion of neuromuscular blocking agents and avoidance or dose reduction of inhalational agents.\[[@ref1][@ref2]\] At our institute, a total intravenous anesthesia (TIVA) protocol devoid of neuromuscular blocking agents is practised. However, prolonged infusion of propofol TIVA is fraught with risks, such as hypotension, delayed awakening, and metabolic acidosis, popularly described as "propofol infusion syndrome."\[[@ref3]\] High doses of opioids are associated with adverse effects, such as postoperative nausea and vomiting, and postoperative respiratory depression that are undesirable in neurosurgical patients. Dexmedetomidine is increasingly used as an anesthetic adjuvant and has been demonstrated to reduce anesthetic requirement and provide hemodynamic stability during neurosurgery.\[[@ref4]\] The only systematic review evaluating dexmedetomidine as an adjuvant during neurosurgery confirmed significant beneficial outcomes such as reduction in intraoperative opioid and anesthetic consumption, lower heart rate and blood pressure, reduced shivering and PONV, lower postoperative pain and analgesic requirement, and early extubation.\[[@ref5]\] However, the beneficial effect of dexmedetomidine has not been tested during TIVA and when neuromuscular blockade is excluded. We hypothesised that high dose of propofol and fentanyl with its consequent adverse effects can be minimized with adjunctive use of dexmedetomidine during electromyogram monitoring for CPA surgeries. This study aimed to evaluate the effect of dexmedetomidine on intraoperative propofol and fentanyl consumption and postoperative recovery characteristics during CPA surgeries.

Material and Methods {#sec1-2}
====================

This was a prospective randomized parallel-group, nonfunded, single-center study conducted at after institutional ethics committee approval. The trial was registered retrospectively at clinical trial registry of India vide registration number CTRI/2017/01/007667.

The primary objective of this study was to confirm the anesthetic sparing effect of dexmedetomidine during TIVA without neuromuscular blocking agents. Secondary objectives were determining the analgesic sparing effect, comparing anesthesia recovery parameters, incidence of adverse intraoperative hemodynamic events, and utilization of other analgesic and hemodynamic drugs.

All consecutive consenting patients of either sex undergoing surgery for CPA tumor and aged between 18 and 60 years were included in this study. Our exclusions were patients with significant cardiovascular involvement as evidenced by arrhythmia on electrocardiogram, baseline heart rate \<50 and \>100/min, hypertension on antihypertensive drugs or cardiac failure, impaired hepatic or renal function, and allergy to egg.

After selection of the eligible patients, randomization to the study group was performed at 1:1 ratio by a computer-generated random number table. Group F received only fentanyl and group D received dexmedetomidine and fentanyl.

On arrival in the operation theatre, intraoperative monitoring (electrocardiograph, pulse oximetry, noninvasive blood pressure, and bispectral index (BIS)) was applied. Anesthesia was induced with propofol 2 mg/kg, fentanyl 2 μg/kg, and lignocaine 1.5 mg/kg. Vecuronium 0.12 mg/kg was administered to facilitate tracheal intubation. Anesthesia was maintained with propofol TIVA via a target controlled infusion (TCI) device \[Fresenius Kabi India Pvt Ltd\] using Schnider pharmacokinetic model, titrated to a BIS target of 40--60. Either fentanyl infusion (0.5 μg/kg/hour) or fentanyl + dexmedetomidine infusion (both at 0.5 μg/kg/hr) was administered based on the randomization from beginning to end of surgery. Neuromuscular blocking agents were excluded (due to institution of cranial nerve EMG monitoring) and additional boluses of 1 μg/kg fentanyl administered at the discretion of attending anesthesiologist based on hemodynamic exacerbations. If an increase in BIS was observed for \>5 minutes with associated hemodynamic activation, a bolus of 1 mg/kg propofol was administered along with an increase in the TCI effect site concentration target of 0.5 μg/mL. The attending anesthesiologist was blinded by providing fentanyl (4 μg/mL) or premixed fentanyl and dexmedetomidine (both 4 μg/mL) as colorless solutions in an unlabelled 50 mL syringe for constant infusion at 0.125 mL/kg/hour.

Hemodynamic measurements were recorded at 5-minute intervals with the aim of detecting adverse hemodynamic events. Hypertension was defined as increase in the mean arterial pressure (MAP) by \>30% of the baseline for \>5 minutes. Hypotension was defined as a decrease in MAP by \>30% of the baseline. Bradycardia was defined as a decrease in heart rate to \<45/minute for \>5 minutes. Tachycardia was defined as an increase in heart rate by \>30% of the baseline for \>5 minutes. When hypotension was observed, fluid bolus and/or transfusion was administered if hypovolemia/blood loss was presumed to be the cause. If hypotension persisted for \>5 min despite the above measures, inj. mephentermine 6 mg boluses were administered and recorded. If bradycardia was associated with hypotension, other than during cranial nerve/brainstem stimulation, atropine 0.01 mg/kg was administered as treatment.

The study drug infusions were stopped at the beginning of skin closure and the patients were administered 1 g paracetamol IV. Time to opening eyes, obeying commands, and extubation were assessed after discontinuation of anesthetics. Extubation was left at the discretion of the attending anesthesiologist; however, any extra drugs administered before extubation were recorded (including antiemetics, antiepileptics, analgesics, hemodynamic agents). All monitoring parameters were also recorded just after extubation.

Sample size calculation {#sec2-1}
-----------------------

Since there was no precedent of a similar study protocol and population in relevant literature, we did a pilot study of four cases in each group to find a difference in propofol consumption. Effect size *d* was found to be 1.2, with total propofol dose of 1804 ± 295 mg in dexmedetomidine group vs. 2327 ± 548 mg in fentanyl group. With a two-tailed hypothesis, and keeping α-error of 0.05 and aiming for a power of 0.95, sample size was found to be 20 in each group. Figuring in an attrition rate of 20%, 25 subjects per group was decided for recruitment.

Statistical analysis {#sec2-2}
--------------------

All statistical tests were performed using SPSS^®^ ver. 16 software (Statistical Package for the Social Sciences, Chicago). Quantitative variables were described as means and standard deviations, qualitative variables as percentages, and variables on ordinal scale as medians and interquartile range. Error bars for graphical depiction of quantitative data indicate standard deviations. Qualitative variables were analyzed between the groups with Chi-square test or Fisher\'s exact test as appropriate. Normally distributed quantitative variables were analyzed using independent samples student *t*-test between the groups and paired samples *t*-test for within-group analysis across time points. Non-normally distributed quantitative data and ordinal data were analyzed using Mann--Whitney *U*-test for between-group comparison and Wilcoxon signed ranks test for within-group comparison across time points. Correlation analysis was conducted using Spearman\'s test. *P* value of \<0.05 was taken as level of statistical significance.

Results {#sec1-3}
=======

50 patients were recruited. One patient in the fentanyl group was excluded due to intraoperative BIS sensor failure. 49 patients (Group D, *n* = 25 and Group F, *n* = 24) were included in final analysis \[[Figure 1](#F1){ref-type="fig"}\].

![CONSORT flow diagram](JOACP-34-496-g001){#F1}

The demographic parameters and perioperative characteristics were comparable between the two groups \[[Table 1](#T1){ref-type="table"}\].

###### 

Demographic variables

  Parameters                      Dexmedetomidine   Fentanyl       *P*
  ------------------------------- ----------------- -------------- -------
  Age (years)                     41.5 (10.5)       41.2 (12.1)    0.924
  Sex (M/F) (%)                   56/44             33/67          0.111
  BMI (kg/m^2^)                   23.81 (4.41)      23.0 (4.1)     0.525
  Duration of Surgery (min)       336.0 (102.6)     339.0 (95.0)   0.919
  Duration of Anaesthesia (min)   394.5 (105.3)     401.3 (94.8)   0.815

Anesthetic and analgesic consumption during surgery {#sec2-3}
---------------------------------------------------

The anesthetic and analgesic doses were compared as such, and after adjustment for total body weight and duration of anesthesia. The extra boluses of propofol and fentanyl required were also compared between the groups. There was a significant reduction in total fentanyl and propofol consumption with use of dexmedetomidine, and the difference persisted after adjustment for body weight and duration of anesthesia. Propofol boluses were infrequently used by the attending anesthesiologists intraoperatively and did not differ significantly between the two groups. The number of fentanyl boluses administered was significantly less in the dexmedetomidine group \[Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}\].

![Propofol requirement during surgery in fentanyl only and dexmedetomidine (with fentanyl) groups](JOACP-34-496-g002){#F2}

![Fentanyl requirement during surgery in fentanyl only and dexmedetomidine (with fentanyl) groups](JOACP-34-496-g003){#F3}

Hemodynamic adverse events {#sec2-4}
--------------------------

The dexmedetomidine group recorded a significantly higher incidence of bradycardia (36% vs. 0%) than the fentanyl group (*P* = 0.002). The incidence of hypertension, hypotension, and tachycardia were not significantly different between the two groups \[[Figure 4](#F4){ref-type="fig"}\]

![Hemodynamic events during surgery in fentanyl only and dexmedetomidine (with fentanyl) groups](JOACP-34-496-g004){#F4}

Anesthesia recovery parameters {#sec2-5}
------------------------------

Most patients (85%) had onset of spontaneous respiration during the intraoperative period as neuromuscular blocking drugs were excluded after the intubating dose was administered. Fentanyl administration and ventilatory adjustment overcame attempts at spontaneous respiration. The mean time to eye opening, time to obeying commands, and time to extubation were higher in dexmedetomidine group, although the difference was not statistically significant \[[Table 2](#T2){ref-type="table"}\].

###### 

Recovery characteristics after surgery in fentanyl only and dexmedetomidine (with fentanyl) groups

                             Dexmedetomidine   Fentanyl   *P*
  -------------------------- ----------------- ---------- -------
  Time to opening eyes       21.1±14.8         13.9±4.7   0.166
  Time to obeying commands   21.8±14.6         15.1±4.7   0.280
  Extubation Time            19.9±13.8         13.5±4.2   0.359

Rescue drug utilization {#sec2-6}
-----------------------

Utilization of labetalol, mephentermine, atropine, and morphine were compared between the two groups as dichotomous variables. Morphine was used as intraoperative analgesic agent at the discretion of the attending anesthesiologist, when fentanyl boluses were deemed to be subefficacious in a given patient, based on hemodynamic variables. There was no significant difference between utilization rates of any of the drugs \[[Table 3](#T3){ref-type="table"}\].

###### 

Rescue drug utilization during surgery in fentanyl only and dexmedetomidine (with fentanyl) groups

                      Dexmedetomidine   Fentanyl   *P*
  ------------------- ----------------- ---------- -------
  Labetalol (%)       12.0              12.5       1.000
  Mephentermine (%)   24.0              8.3        0.247
  Atropine (%)        12.0              0          0.235
  Morphine (%)        8.0               12.5       0.667

Discussion {#sec1-4}
==========

This study reconfirmed the findings of earlier studies regarding anesthetic and analgesic sparing effects of dexmedetomidine during CPA surgeries. Interestingly, despite the reduced propofol and fentanyl consumption, a similar recovery profile was observed in both fentanyl-based and dexmedetomidine-based anesthetic techniques.

We performed a systematic search of the literature for dexmedetomidine as an anesthetic adjunct using Google Scholar and PubMed databases with keywords "dexmedetomidine anesthetic sparing." The search revealed 50 results, which were collated and separated according to the relevance to our keywords. Data regarding significant intraoperative anesthetic/analgesic sparing (yes/no) and recovery parameters (significantly faster times to extubation with dexmedetomidine -- yes/no) was collected. Animal studies, case reports, retrospective studies, review articles, and irrelevant studies were excluded, which resulted in 17 relevant results \[[Table 4](#T4){ref-type="table"}\].

###### 

Results of literature review for anesthetic sparing efficacy of dexmedetomidine

  Author/Year of Publication             Patient population                                        Number of Patients                              Dexmed dose                           Anaesthetic/analgesic      Anaesthetic titration criteria   Anaesthetic Sparing   Analgesic Sparing   Recovery Parameter
  -------------------------------------- --------------------------------------------------------- ----------------------------------------------- ------------------------------------- -------------------------- -------------------------------- --------------------- ------------------- --------------------
  Soliman *et al*/2011[@ref6]            Supratentorial Craniotomy                                 40; 20 per group                                1 µg/kg → 0.4 µg/kg/hr IV             Sevoflurane/Fentanyl       Hemodynamic                      Yes                   Yes                 Yes
  Kanda H *et al*/2009[@ref7]            Cardiovascular Surgery                                    24; 12 per group                                6 µg/kg → 0.7 µg/kg/hr IV             Propofol/Fentanyl          NA                               Yes                   Yes                 NA
  Keniya VM *et al*/2011[@ref8]          Surgery \>3 h duration                                    60; 30 per group                                1 µg/kg → 0.2-0.7 µg/kg/hr IV         Isoflurane/Fentanyl        Hemodynamic                      Yes                   Yes                 No
  Bajwa SJ/2012[@ref9]                   Elective Surgery                                          100; 50 per group                               1 µg/kg IV                            Isoflurane/N2O/Fentanyl    Hemodynamic                      Yes                   Yes                 Yes
  Ravipati P *et al*/2014[@ref10]        Burn Dressing                                             60; 30 per group                                1 µg/kg IM                            Propofol/Ketamine          Hemodynamic                      Yes                   Yes                 Yes
  Khalil *et al*/2013[@ref11]            Off-pump coronary artery bypass grafting                  50; 25 per group                                0.5 µg/kg/hr IV                       NA/Morphine + Fentanyl     Hemodynamic                      NA                    Yes                 Yes
  Patel CR *et al*/2013[@ref12]          Elective Surgery                                          60; 30 per group                                1 µg/kg → 0.2-0.8 µg/kg/hr IV         Sevoflurane/Fentanyl       Entropy                          Yes                   NA                  NA
  Tufanogullari B *et al*/2008[@ref13]   Laparoscopic bariatric surgery                            80; 20 per group                                0.2/0.4/0.8 µg/kg/hr IV               Desflurane/Fentanyl        Hemodynamic                      Yes                   NA                  No
  Vora KS *et al*/2015[@ref14]           Laparoscopic surgery                                      70; 35 per group                                1 µg/kg → 0.5 µg/kg/hr IV             Isoflurane/N2O/Fentanyl    Hemodynamic                      Yes                   Yes                 NA
  Ngwenyama NE *et al*/2008[@ref15]      Posterior spinal fusion                                   36; 12 in Dexmedetomidine/ 24 in Remifentanyl   0.5 µg/kg/hr IV                       Propofol/Remifentanyl      Bispectral Index                 Yes                   No                  NA
  Kang WS *et al*/2012[@ref16]           Breast Surgery                                            20; 10 per group                                1 µg/kg → 0.6 µg/kg/hr IV             Propofol/Remifentanyl      Bispectral Index                 Yes                   NA                  No
  Gupta N *et al*/2013[@ref17]           Paediatric Spinal dysraphism (8-12 yrs)                   36; 18 per group                                1 µg/kg → 0.5 µg/kg/hr IV             Sevoflurane/Fentanyl       Bispectral Index                 Yes                   Yes                 No
  Kunisawa T *et al*/2011[@ref18]        Cardiopulmonary bypass                                    22; 11 per group                                1 µg/kg → 0.7 µg/kg/hr IV             Propofol/Fentanyl          Bispectral Index                 Yes                   NA                  NA
  Wu X *et al*/2015[@ref19]              Elective Surgery                                          90; 30 per group                                0.5/1 µg/kg → 0.17/0.33 µg/kg/hr IV   Propofol/Remifentanyl      Bispectral Index                 Yes                   No                  NA
  Patel A *et al*/2010[@ref20]           Paediatric tonsillectomy and adenoidectomy (2-10 years)   122; 61 per group                               2 µg/kg → 0.7 µg/kg/hr IV             Sevoflurane/N2O/Fentanyl   Hemodynamic                      Yes                   No                  Yes
  Sen S *et al*/2013[@ref21]             Spine surgery                                             70; 35 per group                                1 µg/kg → 0.2 µg/kg/hr IV             Propofol/N2O/Fentanyl      Bispectral Index                 Yes                   NA                  NA
  Turgut N *et al*/2009[@ref22]          Supratentorial Craniotomies                               50; 25 per group                                1 µg/kg → 0.2-1 µg/kg/hr IV           Propofol/Remifentanyl      Bispectral Index                 Yes                   NA                  No

Anesthetic and analgesic sparing effect {#sec2-7}
---------------------------------------

Anesthetic sparing effect of dexmedetomidine was demonstrated in all the articles studying this effect.\[[@ref6][@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22]\] Our study echoes this finding with a significant reduction in propofol utilization. The difference in patient population (infratentorial intracranial procedures), anesthetic technique (neuromuscular blockade-free anesthesia), and the longer duration of surgery (397.8 ± 99.2 min) in our study did not alter this outcome.

With regards to the analgesic consumption, our findings are in agreement with most other studies included in the literature review.\[[@ref6][@ref7][@ref8][@ref9][@ref10][@ref11][@ref14][@ref17]\] Of the three studies with contradicting claims, two studies used remifentanyl as the primary analgesic, which cannot be directly compared with fentanyl, used as analgesic in our study.\[[@ref15][@ref19]\] The third study by Patel *et al.*, included pediatric population for short-duration surgeries and hence also cannot be compared directly.. In this study too, the intraoperative rescue by fentanyl was significantly less in dexmedetomidine group, although the total fentanyl dosages remained comparable.\[[@ref20]\] The discrepancy is probably due to the shorter duration of surgeries in their study (\~70 minutes), which obviates the use of extra fentanyl in the intraoperative period.

Effect on recovery parameters {#sec2-8}
-----------------------------

Of the 10 studies assessing the effect of dexmedetomidine on the time to extubation, 5 documented a shorter time to extubation,\[[@ref6][@ref9][@ref10][@ref11][@ref20]\] 4 found no difference,\[[@ref8][@ref13][@ref16][@ref17]\] and one study observed a longer extubation time.\[[@ref22]\] The study with longer extubation time directly compared dexmedetomidine and remifentanyl as primary analgesic agent and hence such a result is expected due to the shorter half-life of remifentanyl.\[[@ref22]\] The five studies observing a significant reduction in the extubation time used hemodynamic criteria for anesthetic titration as against BIS in our study. Hemodynamic variability when used as an anesthetic titration criterion, leads to overdosing of hypnotic agent with significantly higher propofol infusion rates and total propofol dose.\[[@ref23]\] Considering the hemodynamic depressive effect of dexmedetomidine and a higher propofol/inhalational agent usage with hemodynamic criterion, it is not surprising that these studies found faster times to extubation in the dexmedetomidine group. One of these studies used propofol as the primary anesthetic agent, in short duration burn dressing population with ketamine and dexmedetomidine administered as intramuscular injection for analgesia. Thus, direct comparison with this study is not possible.\[[@ref10]\]

Of the four studies observing no difference in extubation times with dexmedetomidine, three studies had utilized isoflurane, desflurane, and sevoflurane as the anesthetic agents, therefore making direct comparison difficult.\[[@ref8][@ref13][@ref20]\] The study utilizing propofol as the primary anesthetic agent used a fixed dose remifentanyl as the primary analgesic. The other difference from our protocol was the of rocuronium for neuromuscular blockade. The extubation time in that study (9 ± 3 min with dexmedetomidine vs. 11 ± 4 min without) was shorter than our study. This may be explained by the longer operating time in our study and difference in the patient population studied (elective breast surgery vs. CPA surgery).\[[@ref16]\]

The similar recovery times in both the groups in our study despite the lower dose of propofol and fentanyl used in dexmedetomidine group can be explained by the sedation effect of dexmedetomidine which probably negates the effect of reduced dose of propofol and fentanyl.

Hemodynamic adverse events {#sec2-9}
--------------------------

Dexmedetomidine, being a central α-2 agonist, causes reduction in the tonic sympathetic output from the brain and has been shown in most previous studies to result in bradycardia and in some instances, hypotension.\[[@ref24]\] Our study confirms this fact, although the incidence of hypotension was not significantly different from the fentanyl group. CPA surgeries are associated with brainstem manipulation-induced transient bradycardia, which is used as a sign by the surgeon to modify his surgical approach. In our study, we defined bradycardia as heart rate \<45 for \>5 minutes, to rule out brainstem manipulation-induced events. Also, only clinically significant bradycardia (i.e., associated with hypotension) was treated with atropine. Considering the atropine utilization rate, the incidence of clinically relevant bradycardia was not significantly different between the two groups.

Conclusion {#sec1-5}
==========

Dexmedetomidine--fentanyl--propofol anesthesia compares favorably with fentanyl--propofol anesthesia during CPA neurosurgical procedures with respect to recovery characteristics, though propofol and fentanyl consumption is reduced when dexmedetomidine is used as an anesthetic adjuvant. No additional clinical advantage in terms of recovery from anesthesia was obtained by incorporating dexmedetomidine in the currently used anesthetic technique for facilitating cranial nerve monitoring during CPA tumor surgeries.
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